Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AX Other antivirals
J05AX10 Maribavir
D04859 Maribavir (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-cytomegalovirus (CMV) Agents
Maribavir
D04859 Maribavir (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D04859 Maribavir (JAN/USAN/INN)
Drug groups [BR:br08330]
Antiviral
DG01937 Anti-cytomegalovirus agent
D04859 Maribavir
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
D04859 Maribavir
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D04859 Maribavir
Drug classes [BR:br08332]
Antiviral
DG01937 Anti-cytomegalovirus agent
D04859 Maribavir
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
Other inhibitor
D04859 Maribavir (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04859
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04859
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04859
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D04859